Goldman Sachs downgraded NASDAQ:MLTX from Mixed to Sell, reflecting a cautious stance from the investment bank.Despite the downgrade, MLTX shares surged by 9.6%, indicating positive market momentum.Favorable FDA feedback suggests MoonLake may file for skin drug approval without new clinical trials, boosting the company's prospects.MoonLake Immunotherapeutics, trading under the symbol NASDAQ:MLTX, is a biopharmaceutical company focused on developing innovative therapies for inflammatory diseases. Recently, G ...